Loading...

Protalix BioTherapeutics

AMEX:PLX
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PLX
AMEX
$59M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The last earnings update was 63 days ago. More info.


Add to Portfolio Compare Print
  • Protalix BioTherapeutics has significant price volatility in the past 3 months.
PLX Share Price and Events
7 Day Returns
1%
AMEX:PLX
-1.6%
US Biotechs
-0.7%
US Market
1 Year Returns
-6.1%
AMEX:PLX
-5.5%
US Biotechs
3%
US Market
PLX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Protalix BioTherapeutics (PLX) 1% -4% -23.3% -6.1% -50.1% -89.6%
US Biotechs -1.6% -5.5% -6.5% -5.5% 9.7% 12%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • PLX underperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
PLX
Industry
5yr Volatility vs Market

PLX Value

 Is Protalix BioTherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Protalix BioTherapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Protalix BioTherapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Protalix BioTherapeutics. This is due to cash flow or dividend data being unavailable. The share price is $0.399.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Protalix BioTherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Protalix BioTherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AMEX:PLX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.18
AMEX:PLX Share Price ** AMEX (2019-05-17) in USD $0.4
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.48x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Protalix BioTherapeutics.

AMEX:PLX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:PLX Share Price ÷ EPS (both in USD)

= 0.4 ÷ -0.18

-2.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Protalix BioTherapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Protalix BioTherapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Protalix BioTherapeutics's expected growth come at a high price?
Raw Data
AMEX:PLX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
29%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.32x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Protalix BioTherapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Protalix BioTherapeutics's assets?
Raw Data
AMEX:PLX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.36
AMEX:PLX Share Price * AMEX (2019-05-17) in USD $0.4
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.21x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
AMEX:PLX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:PLX Share Price ÷ Book Value per Share (both in USD)

= 0.4 ÷ -0.36

-1.12x

* Primary Listing of Protalix BioTherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Protalix BioTherapeutics has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at Protalix BioTherapeutics's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Protalix BioTherapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Protalix BioTherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Protalix BioTherapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PLX Future Performance

 How is Protalix BioTherapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Protalix BioTherapeutics expected to grow at an attractive rate?
  • Protalix BioTherapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Protalix BioTherapeutics's earnings growth is expected to exceed the United States of America market average.
  • Protalix BioTherapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
AMEX:PLX Future Growth Rates Data Sources
Data Point Source Value (per year)
AMEX:PLX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 29%
AMEX:PLX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 38.4%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AMEX:PLX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AMEX:PLX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 -7 -5
2022-12-31 30 40
2021-12-31 110 114
2020-12-31 72 64 51 1
2019-12-31 16 -27 -23 1
AMEX:PLX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 34 -8 -26
2018-09-30 28 14 -34
2018-06-30 23 -10 -40
2018-03-31 21 -11 -36
2017-12-31 21 -10 -83
2017-09-30 19 -35 -73
2017-06-30 16 -28 -69
2017-03-31 11 -31 -80
2016-12-31 9 -32 -29
2016-09-30 7 -29 -35
2016-06-30 4 -34 -34
2016-03-31 3 -27 -29

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Protalix BioTherapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Protalix BioTherapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AMEX:PLX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Protalix BioTherapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:PLX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.03 -0.03 -0.03 1.00
2022-12-31 0.26 0.26 0.26 1.00
2021-12-31 0.75 0.75 0.75 1.00
2020-12-31 0.35 0.44 0.26 2.00
2019-12-31 -0.15 -0.15 -0.15 1.00
AMEX:PLX Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.18
2018-09-30 -0.24
2018-06-30 -0.29
2018-03-31 -0.26
2017-12-31 -0.64
2017-09-30 -0.59
2017-06-30 -0.60
2017-03-31 -0.74
2016-12-31 -0.29
2016-09-30 -0.35
2016-06-30 -0.35
2016-03-31 -0.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Protalix BioTherapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Protalix BioTherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Protalix BioTherapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PLX Past Performance

  How has Protalix BioTherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Protalix BioTherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Protalix BioTherapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Protalix BioTherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Protalix BioTherapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Protalix BioTherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Protalix BioTherapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:PLX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 34.24 -26.46 11.70 32.55
2018-09-30 28.19 -34.33 12.86 31.97
2018-06-30 23.38 -40.44 11.61 28.29
2018-03-31 20.91 -35.53 12.27 29.87
2017-12-31 21.08 -83.44 12.31 28.06
2017-09-30 18.85 -72.76 12.33 24.55
2017-06-30 16.00 -68.61 11.51 23.22
2017-03-31 11.41 -79.80 10.90 22.21
2016-12-31 9.20 -29.18 10.36 23.61
2016-09-30 7.12 -35.12 8.51 24.31
2016-06-30 3.78 -33.85 8.66 23.20
2016-03-31 3.35 -29.30 8.45 20.08
2015-12-31 4.36 -27.28 8.28 19.03
2015-09-30 -5.89 -30.54 8.97 17.66
2015-06-30 -3.52 -32.53 8.82 19.82
2015-03-31 -2.17 -32.47 8.38 20.09
2014-12-31 3.52 -33.30 10.23 21.22
2014-09-30 14.90 -32.36 9.61 24.53
2014-06-30 14.55 -30.10 9.38 24.06
2014-03-31 14.93 -30.81 9.99 25.56
2013-12-31 -34.74 9.18 24.88
2013-09-30 10.44 -26.78 8.48 24.05
2013-06-30 12.47 -26.51 8.92 24.77
2013-03-31 34.66 -10.04 10.24 27.17
2012-12-31 34.42 -11.62 9.76 28.69
2012-09-30 35.07 -10.65 8.97 29.60
2012-06-30 30.57 -14.05 8.28 31.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Protalix BioTherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Protalix BioTherapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Protalix BioTherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Protalix BioTherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Protalix BioTherapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PLX Health

 How is Protalix BioTherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Protalix BioTherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Protalix BioTherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Protalix BioTherapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Protalix BioTherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Protalix BioTherapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Protalix BioTherapeutics Company Filings, last reported 4 months ago.

AMEX:PLX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -52.88 52.27 37.81
2018-09-30 -47.94 53.47 41.87
2018-06-30 -49.57 52.00 28.33
2018-03-31 -39.44 57.21 41.32
2017-12-31 -29.46 56.49 51.16
2017-09-30 -26.07 63.84 33.48
2017-06-30 -20.67 57.88 34.53
2017-03-31 -68.47 117.51 48.02
2016-12-31 -9.96 77.52 63.28
2016-09-30 -15.10 72.43 51.32
2016-06-30 -7.98 72.32 54.63
2016-03-31 2.65 72.21 66.67
2015-12-31 10.87 72.10 76.37
2015-09-30 -68.51 67.77 34.25
2015-06-30 -65.14 67.67 43.24
2015-03-31 -61.15 67.57 47.96
2014-12-31 -55.60 67.35 54.77
2014-09-30 -47.69 67.36 60.32
2014-06-30 -39.79 67.26 71.14
2014-03-31 -33.58 67.15 77.69
2013-12-31 -26.95 67.05 86.40
2013-09-30 -16.71 66.94 91.40
2013-06-30 -11.99 0.00 33.13
2013-03-31 -6.28 0.00 41.87
2012-12-31 -3.36 0.00 52.04
2012-09-30 4.77 0.00 50.22
2012-06-30 7.86 0.00 59.28
  • Protalix BioTherapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Protalix BioTherapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Protalix BioTherapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Protalix BioTherapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -46.4% each year.
X
Financial health checks
We assess Protalix BioTherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Protalix BioTherapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PLX Dividends

 What is Protalix BioTherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Protalix BioTherapeutics dividends.
If you bought $2,000 of Protalix BioTherapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Protalix BioTherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Protalix BioTherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AMEX:PLX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AMEX:PLX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Protalix BioTherapeutics has not reported any payouts.
  • Unable to verify if Protalix BioTherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Protalix BioTherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Protalix BioTherapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Protalix BioTherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Protalix BioTherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Protalix BioTherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PLX Management

 What is the CEO of Protalix BioTherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Moshe Manor
COMPENSATION $717,654
AGE 62
TENURE AS CEO 4.5 years
CEO Bio

Mr. Moshe Manor has been the Chief Executive Officer and President of Protalix BioTherapeutics, Inc. since November 01, 2014. Mr. Manor is the Founder and Owner MACOI. Mr. Manor served as the Chief Executive Officer of Teva Asia & Pacific at Teva Pharmaceutical Industries Limited and served as its President of Teva Asia & Pacific since October 2010, President of Asia Region since August 2010, Group Vice President of Global Branded Products from January 2009 to August 2010, Group Vice President of Global Innovative Resources from 2006 to 2008 and Vice President of Global Products Division from 2002 to January 2006. Mr. Manor brings an extensive and diverse experience acquired during the last 28 years at Teva Pharmaceutical Industries in various positions, both with line and staff responsibility, in the generics and innovative arenas. He has served in a number of senior executive positions at Teva Pharmaceutical Industries Limited from 1984 to 2012. He served as a Vice President of Global Products Division at Teva Pharmaceutical Finance LLC since 2002. Mr. Manor served as Vice President of Strategic Product Planning at Teva Pharmaceutical Finance LLC from 2000 to 2002 and as Vice President Israel Pharmaceutical Sales from 1995 to 2000. He served as the General Manager of Teva-labeled products in Israel from 1993 to 1994 and as the Marketing Director of the Israeli Pharmaceutical Division from 1989 to 1993. He serves as the Chairman of MEway Pharma LTD. He has been a Director of Protalix BioTherapeutics, Inc. since November 01, 2014 and Coronis NeuroSciences Ltd. He served as a Director of Kamedis Ltd. Previously, he served as Director of Teva Israel. Mr. Manor served on the Board of Directors of Coronis Partners. Mr. Manor holds a B.A. in Economics from the Hebrew University in 1982 and his M.B.A. from Tel Aviv University in 1985.

CEO Compensation
  • Moshe's compensation has been consistent with company performance over the past year.
  • Moshe's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Protalix BioTherapeutics management team in years:

10.5
Average Tenure
58
Average Age
  • The average tenure for the Protalix BioTherapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Moshe Manor

TITLE
CEO, President & Director
COMPENSATION
$718K
AGE
62
TENURE
4.5 yrs

Yoseph Shaaltiel

TITLE
Founder and Executive VP Research & Development
COMPENSATION
$433K
AGE
64
TENURE
12.4 yrs

Yossi Maimon

TITLE
CFO, VP
COMPENSATION
$558K
AGE
47
TENURE
12.4 yrs

Yaron Naos

TITLE
Senior Vice President of Operations
COMPENSATION
$339K
AGE
54
TENURE
1 yrs

Einat Brill-Almon

TITLE
Senior Vice President of Product Development
COMPENSATION
$504K
AGE
58
TENURE
12.4 yrs

Dafna Shelly

TITLE
Vice President of Human Resources
TENURE
8.5 yrs
Board of Directors Tenure

Average tenure and age of the Protalix BioTherapeutics board of directors in years:

4.7
Average Tenure
71
Average Age
  • The tenure for the Protalix BioTherapeutics board of directors is about average.
Board of Directors

Shlomo Yanai

TITLE
Chairman of the Board
COMPENSATION
$200K
AGE
66
TENURE
4.8 yrs

Moshe Manor

TITLE
CEO, President & Director
COMPENSATION
$718K
AGE
62
TENURE
4.5 yrs

Roger Kornberg

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
$55K
AGE
71

Zeev Bronfeld

TITLE
Independent Director
COMPENSATION
$80K
AGE
67
TENURE
12.4 yrs

Amos Shalev

TITLE
Independent Director
COMPENSATION
$80K
AGE
65
TENURE
10.8 yrs

J. Ciechanover

TITLE
Member of Scientific Advisory Board
AGE
71
TENURE
11.8 yrs

Aharon Schwartz

TITLE
Independent Director
COMPENSATION
$66K
AGE
75
TENURE
4.5 yrs

Alexander Levitzki

TITLE
Member of Scientific Advisory Board
AGE
78

Charles Arntzen

TITLE
Member of Scientific Advisory Board
AGE
77
TENURE
2.9 yrs

David Granot

TITLE
Independent Director
COMPENSATION
$20K
AGE
71
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Protalix BioTherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Protalix BioTherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PLX News

Simply Wall St News

What Kind Of Shareholders Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Companies that have been privatized tend to have low insider ownership. … Protalix BioTherapeutics is not a large company by global standards.

Simply Wall St -

Did You Manage To Avoid Protalix BioTherapeutics's Devastating 91% Share Price Drop?

In fact the share price has glided down a mountain to land 91% lower after that period. … The important question is if the business itself justifies a higher share price in the long term. … Protalix BioTherapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS).

Simply Wall St -

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Is Expected To Breakeven

Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX):. … Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. … With the latest financial year loss of -US$85.3m and a trailing-twelve month of -US$51.4m, the US$64m market-cap alleviates its loss by moving closer towards its target of breakeven.

Simply Wall St -

Protalix BioTherapeutics Inc (NYSEMKT:PLX): How Does It Impact Your Portfolio?

Generally, an investor should consider two types of risk that impact the market value of PLX. … The other type of risk, which cannot be diversified away, is market risk. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one.

Simply Wall St -

Why Protalix BioTherapeutics Inc's (NYSEMKT:PLX) Investor Composition Impacts Your Returns

Today, I will be analyzing Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure of a company has been found to affect share performance over time. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Analysts Expect Breakeven For Protalix BioTherapeutics Inc (NYSEMKT:PLX)

Protalix BioTherapeutics Inc's (NYSEMKT:PLX):. … The US$65.51m market-cap posted a loss in its most recent financial year of -US$85.28m and a latest trailing-twelve-month loss of -US$35.53m shrinking the gap between loss and breakeven. … Check out our latest analysis for Protalix BioTherapeutics

Simply Wall St -

Protalix BioTherapeutics Inc's (NYSEMKT:PLX) Profit Outlook

Protalix BioTherapeutics Inc's (AMEX:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. … I’ve also compiled a list of important aspects you should look at: Historical Track Record: What has PLX's performance been like over the past? … Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

Simply Wall St -

Does Protalix BioTherapeutics Inc's (PLX) Past Performance Indicate A Weaker Future?

In this article, I will take a look at Protalix BioTherapeutics Inc's (AMEX:PLX) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … AMEX:PLX Income Statement Dec 7th 17 We can further assess Protalix BioTherapeutics's loss by looking at what has been happening in the industry on top of within the company. … This suggests that any tailwind the industry is profiting from, Protalix BioTherapeutics has not been able to reap as much as its industry peers.What does this mean?

Simply Wall St -

PLX Company Info

Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.

Details
Name: Protalix BioTherapeutics, Inc.
PLX
Exchange: AMEX
Founded: 1993
$59,204,537
148,382,299
Website: http://www.protalix.com
Address: Protalix BioTherapeutics, Inc.
2 Snunit Street,
Science Park,
Karmiel,
21000,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX PLX Ordinary Shares NYSE MKT LLC US USD 03. Jan 2007
DB PBD Ordinary Shares Deutsche Boerse AG DE EUR 03. Jan 2007
TASE PLX Ordinary Shares The Tel-Aviv Stock Exchange IL ILS 03. Jan 2007
Number of employees
Current staff
Staff numbers
184
Protalix BioTherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 01:38
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/06
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.